We are live on ! Find out more
OPRX icon

OptimizeRx

110 hedge funds and large institutions have $168M invested in OptimizeRx in 2025 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

343% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 7

147% more call options, than puts

Call options by funds: $3.09M | Put options by funds: $1.25M

65% more capital invested

Capital invested by funds: $102M → $168M (+$66.6M)

28% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 25

26% more funds holding

Funds holding: 87110 (+23)

3.89% more ownership

Funds ownership: 63.47%67.35% (+3.9%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
110
Holders Change
+23
Holders Change %
+26.44%
% of All Funds
1.45%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
31
Increased
32
Reduced
25
Closed
7
Calls
$3.09M
Puts
$1.25M
Net Calls
+$1.84M
Net Calls Change
+$3.44M

OPRX Hedge Fund Activity: Q2 2025 in Review

110 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q2 2025, worth a combined $168M — up 65% from $102M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new OPRX positions and 7 closed out — a net gain of 24 holders — while 32 added to existing stakes and 25 trimmed.

The largest buyer was Manatuck Hill Partners, adding an estimated $2.9M. The largest seller was Invesco, exiting entirely with an estimated $2.54M sold.

  • 110 institutional investors held OptimizeRx (OPRX) as of Q2 2025, up from 87 in Q1 2025.
  • Funds reported $168M of OptimizeRx stock for Q2 2025, up 65% quarter-over-quarter.
  • 31 funds opened new OptimizeRx positions in Q2 2025 and 7 closed out, a net change of +24 holders.
  • The largest OptimizeRx buyer in Q2 2025 was Manatuck Hill Partners, an estimated $2.9M added.
  • The largest OptimizeRx seller in Q2 2025 was Invesco, an estimated $2.54M sold.

Based on aggregated 13F filings for Q2 2025.